Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2): A randomized clinical trial-Rationale and design

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Validation of the all-comers design: Results of the TARGET-AC substudy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dynamic LED-light versus static LED-light for depressed inpatients: study protocol for a randomised clinical study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Josef Dankiewicz
  • Tobias Cronberg
  • Gisela Lilja
  • Janus Christian Jakobsen
  • Jan Bělohlávek
  • Clifton Callaway
  • Alain Cariou
  • Glenn Eastwood
  • David Erlinge
  • Jan Hovdenes
  • Michael Joannidis
  • Hans Kirkegaard
  • Michael Kuiper
  • Helena Levin
  • Matt P G Morgan
  • Alistair D Nichol
  • Per Nordberg
  • Mauro Oddo
  • Paolo Pelosi
  • Christian Rylander
  • Manoj Saxena
  • Christian Storm
  • Fabio Taccone
  • Susann Ullén
  • Matthew P Wise
  • Paul Young
  • Hans Friberg
  • Niklas Nielsen
View graph of relations

BACKGROUND: Less than 500 participants have been included in randomized trials comparing hypothermia with regular care for out-of-hospital cardiac arrest patients, and many of these trials were small and at a high risk of bias. Consequently, the accrued data on this potentially beneficial intervention resembles that of a drug following small phase II trials. A large confirmatory trial is therefore warranted.

METHODS: The TTM2-trial is an international, multicenter, parallel group, investigator-initiated, randomized, superiority trial in which a target temperature of 33°C after cardiac arrest will be compared with a strategy to maintain normothermia and early treatment of fever (≥37.8°C). Participants will be randomized within 3 hours of return of spontaneous circulation with the intervention period lasting 40 hours in both groups. Sedation will be mandatory for all patients throughout the intervention period. The clinical team involved with direct patient care will not be blinded to allocation group due to the inherent difficulty in blinding the intervention. Prognosticators, outcome-assessors, the steering group, the trial coordinating team, and trial statistician will be blinded. The primary outcome will be all-cause mortality at 180 days after randomization. We estimate a 55% mortality in the control group. To detect an absolute risk reduction of 7.5% with an alpha of 0.05 and 90% power, 1900 participants will be enrolled. The main secondary neurological outcome will be poor functional outcome (modified Rankin Scale 4-6) at 180 days after arrest.

DISCUSSION: The TTM2-trial will compare hypothermia to 33°C with normothermia and early treatment of fever (≥37.8°C) after out-of-hospital cardiac arrest.

Original languageEnglish
JournalAmerican Heart Journal
Volume217
Pages (from-to)23-31
Number of pages9
ISSN0002-8703
DOIs
Publication statusPublished - 26 Jun 2019

ID: 58262274